Bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: A randomized, placebo-controlled, double-blind clinical trial

BMC Urology

Volumn 17, Issue 1, 2017, Pages

  Leitner, Lorenz ^a,b   Sybesma, Wilbert ^a   Chanishvili, Nina ^c   Goderdzishvili, Marina ^c   Chkhotua, Archil ^d   Ujmajuridze, Aleksandre ^d   Schneider, Marc P ^a   Sartori, Andrea ^a   Mehnert, Ulrich ^a   Bachmann, Lucas M ^e   Kessler, Thomas M ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c George Eliava Institute of Bacteriophage Microbiology and Virology   (Georgia)

^d A Tsulukidze National Centre of Urology   (Georgia)

^e MEDIGNITION INC   (Switzerland)

Author keywords

Antibiotics; Bacteriophages; Randomized placebo controlled double blind trial; Resistance; Urinary tract infection

Indexed keywords

ANTIBIOTIC AGENT;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHAGE THERAPY; RANDOMIZED CONTROLLED TRIAL; TRANSURETHRAL RESECTION; URINALYSIS; URINARY TRACT INFECTION; URINE CULTURE; BACTERIOPHAGE; GROWTH, DEVELOPMENT AND AGING; PROCEDURES; TREATMENT OUTCOME;

BACTERIOPHAGES; DOUBLE-BLIND METHOD; HUMANS; MALE; PHAGE THERAPY; TRANSURETHRAL RESECTION OF PROSTATE; TREATMENT OUTCOME; URINARY TRACT INFECTIONS;

EID: 85029887246     PISSN: None     EISSN: 14712490     Source Type: Journal    
DOI: 10.1186/s12894-017-0283-6     Document Type: Article

References (21)

1. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med. 2002;113(Suppl 1A):5S-13S.
2. Ruden H, Gastmeier P, Daschner FD, Schumacher M. Nosocomial and community-acquired infections in Germany. Summary of the results of the First National Prevalence Study (NIDEP). Infection. 1997;25(4):199-202.
3. Carlet J, Collignon P, Goldmann D, Goossens H, Gyssens IC, Harbarth S, Jarlier V, Levy SB, N'Doye B, Pittet D, et al. Society's failure to protect a precious resource: antibiotics. Lancet. 2011;378(9788):369-71.
4. Verbeken G, Huys I, Pirnay JP, Jennes S, Chanishvili N, Scheres J, Gorski A, De Vos D, Ceulemans C. Taking bacteriophage therapy seriously: a moral argument. Biomed Res Int. 2014;2014:621316.
5. Holmes AH, Moore LS, Sundsfjord A, Steinbakk M, Regmi S, Karkey A, Guerin PJ, Piddock LJ. Understanding the mechanisms and drivers of antimicrobial resistance. Lancet. 2016;387(10014):176-87.
6. Mazzulli T. Resistance trends in urinary tract pathogens and impact on management. J Urol. 2002;168(4 Pt 2):1720-2.
7. Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM. Phage treatment of human infections. Bacteriophage. 2011;1(2):66-85.
8. Chanishvili N. A Literature Review of the Practical Application of Bacteriophage Research. Nova Science Publishers. 2012
9. Merabishvili M, Vervaet C, Pirnay JP, De Vos D, Verbeken G, Mast J, Chanishvili N, Vaneechoutte M. Stability of Staphylococcus aureus phage ISP after freeze-drying (lyophilization). PLoS One. 2013;8(7):e68797.
10. Khawaldeh A, Morales S, Dillon B, Alavidze Z, Ginn AN, Thomas L, Chapman SJ, Dublanchet A, Smithyman A, Iredell JR. Bacteriophage therapy for refractory Pseudomonas aeruginosa urinary tract infection. J Med Microbiol. 2011;60(Pt 11):1697-700.
11. Expert round table on a, re-implementation of bacteriophage t: Silk route to the acceptance and re-implementation of bacteriophage therapy. Biotechnol J 2016, 11(5):595-600.
12. Sybesma W, Zbinden R, Chanishvili N, Kutateladze M, Chkhotua A, Ujmajuridze A, Mehnert U, Kessler TM. Bacteriophages as Potential Treatment for Urinary Tract Infections. Front Microbiol. 2016;7:465.
13. Perepanova T, Debreeva O, Koliatarova G, Kondratieva E, Aitskaia I, Malysheva V, al. e: The efficacy of bacteriophages preparations in treatment of inflammatory urogenital diseases. Urology & Nephrology 1957;5:14-17.
14. Kolomintsev N, Goroeinko I, Shakmatov V, Brazhnik P. Treatment of urological infections with different antibiotics and specific coli-proteus bacteriophages. Strategy and tactics of antibiotic therapy Krasnodar. 1966:172-4.
15. Danilova T. Phage therapy of the inflammatory urogenital infections in women. Proceedings of Dermatology and Venerology. 1996
16. Merabishvili M, Pirnay JP, Verbeken G, Chanishvili N, Tediashvili M, Lashkhi N, Glonti T, Krylov V, Mast J, Van Parys L, et al. Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS One. 2009;4(3):e4944.
17. Pirnay JP, De Vos D, Verbeken G, Merabishvili M, Chanishvili N, Vaneechoutte M, Zizi M, Laire G, Lavigne R, Huys I, et al. The phage therapy paradigm: pret-a-porter or sur-mesure? Pharm Res. 2011;28(4):934-7.
18. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A. Standardisation Sub-committee of the International Continence S: The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167-78.
19. Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett AT. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992;148(5):1549-57. discussion 1564
20. Declaration of Helsinki - Ethical principles for medical research involving human subjects. [ https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects ].
21. Good clinical practice guideline [ http://www.ich.org/products/guidelines/efficacy/article/efficacy-guidelines.html ].